[ GLIA ]
>> Honorable mention to those from our old list...... GLIA,
REGN and HYSQ<<
There's news out today for GLIA......
prnewswire.com
GLIA always seems to be slow to react to news. It has very little coverage, and many of the investors seem to be local to Cleveland and to obtain their news from the daily newspaper. I'm not encouraging anybody to run into news that is already out, but.......
it may soon sink in that this is favorable labeling for 400K X approximately $400 per procedure, or a U.S. market of about $160 million. Investors will start to realize that there are only 7.4 million shares out, and that only 10% penetration of the U.S. market will be about $2/share of revenue. Add that (1) we're waiting for approval of reimbursement in key european countries, (2) the Alzheimer's program with Janssen (Johnson and Johnson) has recently been renewed (leads are in optimization), (3) the H3R antagonist program is not yet partnered but has already attracted the attention of at least one pharma, (4) Adcon-L sales in Europe are already ramping up, and (5) Adcon-T/N is coming along and addresses a market that is similar in size to that of Adcon-L, and it would seem that we're markedly undervalued.
I don't usually set targets. There's probably some dilution coming, but.... given the labeling that FDA is allowing for this product and the data for resurgery that seems to have gone unchallenged.... I feel that penetration of the U.S. market will be simpler than generally accepted, and that a 12 month target of $50/share is not unreasonable.
Trading today? I don't understand why we're not at $20/share. Margins are currently decent from sales in Europe, and U.S. sales will be through distributors. Most of those revenues should go to the bottom line. I think that, once we clear those sellers who don't understand the company, that we're going up.
Just my opinion. Get your own.
Cheers! Rick |
